Home-Based Neurofeedback Program in Treating Participants with Chemotherapy-Induced Peripheral Neuropathy

Inclusion Criteria

• Patients must have the ability to understand and read English, sign a written informed consent, and be willing to follow protocol requirements.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
• Neuropathic pain score >= 4 on a 0-10 numeric pain scale (numeric rating scale [NRS]) and/or grade 3 or higher neuropathic symptoms according to the National Cancer Institute’s 4 point grading scale.
• Neuropathic symptoms must be related to chemotherapy (in the opinion of the treating physician).
• Patients must have had neuropathic symptoms for a minimum of 3 months.
• No plans to change pain medication regimen during the course of the study.
• Off active chemotherapy treatment for minimum of 6 months.
• Hormonal (e.g., tamoxifen or arimidex, etc.) and targeted (tarceva and avastin, etc.) therapies allowed as long as they will be continued during the course of the study.
• Willing to come to MD Anderson for the intake and follow up data acquisition and to receive their equipment.
• Willing to allow research staff to come to their homes or to return the equipment to MD Anderson (MDA) in the case of equipment malfunction.
• Have had a diagnosis of cancer treated with chemotherapy.
• Live within a 50 mile radius of MD Anderson’s main campus.

Exclusion Criteria

• Patients who are taking any antipsychotic medications.
• Patients with active central nervous system (CNS) disease, such as clinically-evident metastases or leptomeningeal disease, dementia, or encephalopathy.
• Patients who have ever been diagnosed with bipolar disorder or schizophrenia.
• Patients with known, previously diagnosed peripheral neuropathy from causes other than chemotherapy.
• Patients who have a history of head injury or who have known seizure activity.